Factors influencing survival in myelodysplastic syndromes in a Brazilian population: Comparison of FAB and WHO classifications

Leukemia Research

Volumn 28, Issue 6, 2004, Pages 587-594

  Lorand Metze, Irene ^a   Pinheiro, Mariana P ^a   Ribeiro, Elisangela ^a   De Paula, Erich V ^a   Metze, Konradin ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Bone marrow; FAB; IPSS; Myelodysplastic syndromes; Survival; WHO

Indexed keywords

5Q- SYNDROME; ADOLESCENT; ADULT; ARTICLE; BLOOD; BLOOD CELL COUNT; BONE MARROW; BRAZIL; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOLOGY; DISEASE CLASSIFICATION; FEMALE; HUMAN; KARYOTYPING; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SCHOOL CHILD; SIDEROBLASTIC ANEMIA; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANEMIA, SIDEROBLASTIC; BLOOD CELL COUNT; BONE MARROW; BRAZIL; CELL LINEAGE; CHILD; FEMALE; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

EID: 2142728646     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.11.001     Document Type: Article

References (42)

1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 51:1982;189-199
2. Germing U., Gatterman N., Aivado M., Hildebrandt B., Aul C. Two types of acquired idiopathic sideroblastic anemia (AISA): A time-tested distinction. Br J Haematol. 108:2000;724-728
3. Koc S., Harris J.W. Sideroblastic anemias: variations on imprecision in diagnostic criteria, proposal for a extended classification of sideroblastic anemias. Am J Hematol. 57:1998;1-6
4. Oguma S., Yoshida Y., Uchino H., Maekawa T., Nomura T., Mizogushi H. Clinical characteristics of japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Leuk Res. 19:1995;219-225
5. Balduini C.L., Guarnone R., Pecci A., Centenara E., Invernizzi R., Ascari E. The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution. Haematologica. 84:1999;12-16
6. Rosati S., Mick R., Xu F., Stonys E., LeBeau M.M., Larson R., Vardiman J.W. Refractory citopenia with multilineage dysplasia: further characterization on a "unclassifiable" myelodysplastic syndrome. Leukemia. 59:1996;425-433
7. Cermák J., Michalová K., Brezinová J., Zemanová Z. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q-syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res. 27:2003;221-229
8. Sanz G.F., Sanz M.A., Vallespi T., Cañizo M.C., Torrabadella M., Garcia S., San Miguel J.F. Two regression models and scoring system for predicting survival and planning treatment in myelodyspastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood. 74:1998;395-408
9. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization classification of the myeloid neoplasms. Blood. 100:2002;2292-2302
10. Strupp C., Gattermann N., Giagounidis A., Aul C., Hildebrandt B., Haas R., Germing U. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to WHO proposals. Leuk Res. 27:2003;397-404
11. Greenberg P., Cox C., Le Beau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079-2088
12. Goasguen J.E., Bennett J.M. Classification and morphologic features of the myelodysplastic syndromes. Semin Oncol. 19:1992;4-13
13. Lambertenghi-Deliliers G., Annaloro C., Oriani A., Soligo D., Pozzoli E., Polli E.E. Prognostic relevance of bone marrow biopsy findings in myelodysplastic syndromes. Ann Haematol. 66:1993;85-91
14. Lorand-Metze I., Meira D.G., Vassallo J., Lima C.S.P., Metze K. The differential diagnosis between aplastic anemia and hypocellular myelodysplasia in patients with pancytopenia. Haematologica. 84:1999;564-565
15. Maschek H., Georgii A., Kaloutsi V. Myelofibrosis in primary myelodysplastic syndromes. Eur J Haematol. 48:1992;208-214
16. Rosati S., Anastasi J., Vardiman J.W. Recurring problems in the pathology of the myelodysplastic syndromes. Semin Hematol. 33:1996;111-126
17. Members of the MDS study group. Correspondence. Journal of Clinical Oncology 2000;18:3447-52.
18. Germing U., Gatterman N., Strupp C., Aivado M., Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: A retrospective analysis of 1600 patients. Leukemia Res. 24:2000;983-992
19. Nösslinger T., Reisner R., Koller E., Grüner H., Tüchler H., Nowotny H., Pittermann E., Pfeilstöcker M. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood. 98:2002;2935-2941
20. Germing U., Gattermann N., Minning H., Heyll A., Aul C. Problems in the classification of CMML-dysplastic versus proliferative type. Leuk Res. 22:1998;871-878
21. Nösslinger T., Reisner R., Grüner H., Tüchler H., Nowotny H., Pittermann E., Pfeilstöcker M. Dysplastic versus proliferative CMML - a retrospective analysis of 91 patients from a single institution. Leuk Res. 25:2001;741-747
22. Boultwood J., Lewis S., Wainscoat J.S. The 5q-syndrome. Blood. 84:1994;3253-3260
23. Saad S.T.O., Vassallo J., Arruda V.A., Lorand-Metze I. The role of bone marrow study in diagnosis and prognosis of myelodysplastic síndrome. Pathologica. 86:1994;47-51
24. Magalhães S.M.M., Rocha F.D.F., Vassallo J., Pinheiro M.P., Metze K., Metze L.I. Bone Marrow lymphoid aggregates in myelodysplastic syndromes: incidence. Leuk Res. 26:2002;525-530
25. Ramos F., Fernandez-Ferrero S., Suarez D., Barbon M., Rodrigues J.A., Gil S. Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk. Res. 23:1999;283-290
26. Reizenstein P., Ost A. What is MDS? Minimal diagnostic criteria for myelodysplastic syndrome in clinical practice. Leuk. Res. 16:1992;1-11
27. Hasle H., Niemeyer C.M., Chessells J.M., Baumann I., Bennett J.M., Head D.R. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 17:2003;277-282
28. Kaplan E.L., Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481
29. Cox D.R. Regression models and life tables. J R Stat Soc. 34:1972;187
30. Altman D.G., Andersen P.K. Bootstrap investigation of the stability of a Cox regression model. Stat Med. 8:1989;771-783
31. Steyerberg E.W., Bleeker S.E., Moll H.Á., Grobbee D.E., Moons K.G.M. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epid. 56:2003;441-447
32. Metze K., Lobo A.M., Lorand-Metze I. Nucleolus organizer regions (AgNORs) and total tumor mass are independent prognostic parameters for treatment-free period in chronic lymphocytic leukemia. Int J. Cancer (Pred. Oncol.). 89:2000;440-443
33. Lee J.H., Lee J.H., Shin Y.R., Lee J.S., Kim W.K., Chi H.S., et al. Application of different prognostic scoring systems and comparison of the FAB and the WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia. 17:2003;305-313
34. Wei-Li Zhao, Lan Xu, Wen Wu, Hua yan, Wei Tang, et al. The myelodysplastic syndromes: analysis of prognostic systems in 128 Chinese patients from a single institution. Hematol J 2002;3:137-44.
35. Paydas S., Kokak R. Younger age observation in myelodysplastic syndromes. Leuk. Res. 20:1996;367
36. Rego M.F.N., Silva G.P., Metze K., Lorand-Metze I. Acute leukemias in Piauí: comparison to features observed in other regions of Brazil. Braz J Med Biol Res. 36:2003;331-337
37. Arruda V.R., Lima C.S.P., Grignoli C.R.E., Melo M.B., Lorand-Metze I., Alberto F.L., et al. Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. Eur J Haematol. 66:2001;383-388
38. Lopes L.F., Lorand-Metze I., Niero-Melo L., Tone L.G., Velloso E., Campanaro C.M., et al. The brazilian pediatric myelodysplastic cooperative group strategies: Are they relevant to improve educational approach and correct diagnosis? Leukemia Res. 26:2002;637-642
39. Ribeiro E, Lima CSP, Metze K, Lorand-Metze I. Flow cytometric analysis of the expression of Fas/FasL in the bone marrow CD34+ cells in myelodysplastic syndromes: relation to disease progression Leuk Lymph 2004;45:309-13.
40. Bennett J. The World Health Organization (WHO) classification of acute leukemias and the myelodysplastic syndromes. Int J Hematol. 72:2000;131-133
41. Sashida G., Takaku T.I., Shoji N., Nishmaki J., Ito Y., Miyazawa K., et al. Clinico-hematologic features of myelodysplastic syndrome presenting as isolated thrombocytopenia an entity with a relatively favorable prognosis. Leuk Lymph. 44:2003;653-658
42. Barrett J., Saunthararajah Y., Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 37:2000;15-29